

Ajanta House, Charkop, Kandivli (West), Mumbai 400 067 India T +91 22 6606 1000 F +91 22 6606 1200

E info@ajantapharma.com

W www.ajantapharma.com

3rd October 2022

| BSE LIMITED | National Stock Exchange of India, |
|-------------------------------------|---|
| Phiroze Jeejeebhoy Towers | Exchange Plaza, 5 th Floor, Plot no. |
| Dalal Street, | C/1, G Block, Bandra Kurla Complex, |
| Mumbai – 400001 | Bandra (East), Mumbai – 400 051 |
| Scrip Code: BSE – AJANTPHARM 532331 | Scrip Code: NSE AJANTPHARM EO |

Re: Compliance with Reg. 27(2) of the Listing Regulations - Report on Corporate Governance

Dear Sir/Madam,

Pursuant to Regulation 27(2) of the Listing Regulation, enclosed please find:

- 1. Quarterly Compliance Report on Corporate Governance (CG) for the quarter ended on 30th September 2022;
- 2. CG report for the half year ended 30th September 2022, in the prescribed format;
- 3. Certificate for disclosure of loans/guarantees/comfort letters/securities etc. for the half year ended 30th September 2022.

Thanking You,

Yours faithfully,

GAURANG SHAH VP - Legal & Company Secretary

Encl.: a/a



Format of report on Corporate Governance to be submitted by listed entity on quarterly basis

 Name of Listed Entity
Quarter ending : Ajanta Pharma Limited : 30th September 2022

HAR

MUMBAI

| Titl | Name of the | PAN\$ | Category | Initial Date | Date of Re- | Date | Tenure | Date of | No of | No of | Number of | No of post |
|-----------|--------------------------|--------------------------|-----------------------------|------------------|--|------------|--------|-------------|------------------|-----------------|--------------------|-----------------------|
| e (Mr. | Director | & DIN | (Chairperson /Executive/ | of Appointmen | appointment | of Cess | * | Birth | Direct orship | Indepen dent | membershi ps in | of Chairperson |
| 1 | | | Non- | t | | ation | | | in | Director | Audit/ | in Audit/ |
| Ms.) | Section 1 | | Executive/ | - | | | | | listed | ship in | Stakeholde | Stakeholder |
| | | | independent/ | | | | - | | entitie | listed | r | Committee |
| | | | Nominee) & | | | | | 8.4 U S 1 S | S | entities | Committee | held in |
| | | | | | 1. | 1919 | | | includi | includin | (s) | listed |
| | | | en Smelet (3 | | | a | | | ng this | g this | including | entities |
| | | | | | | | | | listed | listed | this listed | including |
| | | | | | | | | | entity (in | entity [in | entity (Refer | this listed entity |
| | | | | | | | | | refere | referen | Regulation | (Refer |
| | | | | | | | | | nce to | ce to | 26(1) of | Regulation |
| | | | | | 10 | | | | Regula | proviso | Listing | 26(1) of |
| | | | | | | | | | tion | to | Regulation | Listing |
| | | | | | | | | | 17A | regulati | s) | Regulations) |
| | | | | | | | | | (1) | on 17A (1)] | | |
| Mr. | Mannalal B. | AACPA2742D | Chairperson & | 31.12.1979 | 04.08.2022 | - | | 26.03.1947 | 1 | 0 | Audit - 1 | Of 1 SRC |
| | Agrawal | & 00073828 | Non-Executive Director | | # | | | | | | SRC - 1 | Committee |
| Mr. | Madhusudan B. Agrawal | AAHPA8178J & | Executive Director | 31.12.1979 | 01.04.2020 | | - | 29.03.1955 | 1 | 0 | None | None |
| | D. Agrawal | 00073872 | Director | | | | | | | | | |
| Mr. | Yogesh M. | AACPA2793C | Executive | 29.04.2000 | 01.04.2018 | - (| - | 14.01.1972 | 1 | 0 | None | None |
| | Agrawal | ይ 00073673 | Director | | | | | | | | | |
| Mr. | Rajesh M. | AACPA2792D | Executive | 30.04.2013 | 01.05.2018 | - | - | 31.03.1976 | 1 | 0 | Audit - | None |
| | Agrawal | ६ 00302467 | Director | | | | | | | | None SRC - 1 | |

| Mr. | Chandrakant Khetan | AAHPK5606M & 00234118 | Independent Director | 20.10.2008 | 18.07.2019 | - | 167 months | 24.01.1946 | 1 | 1 | Audit - 1 SRC - None | Of 1 Audi Committee |
|-----|-----------------------|-----------------------------|-------------------------|------------|------------|---|----------------|------------|---|---|-----------------------------|-------------------------------------|
| Mr. | K H Viswanathan | ALJPK1873B & 06563472 | Independent Director | 30.04.2013 | 18.07.2019 | - | 113 months | 11.01.1946 | 1 | 1 | Audit - 1 SRC - None | None |
| Mr. | Prabhakar Dalal | A¤A¤A7258G & 00544948 | Independent Director | 13.06.2014 | 18.07.2019 | - | 98.5 months | 09.01.1953 | 2 | 2 | Audit - 3 (*) SRC - 1 | Of 1 Audit Committee Of 1 SRC |
| Dr. | Anjana Grewal | AFNPG6211K & 06896404 | Independent Director | 13.06.2014 | 18.07.2019 | - | 98.5 months | 01.11.1953 | 1 | 1 | SRC - 1 | None |

| 1 | II. Composition of C | committees | | | | |
|----------------|--|---|---|--|--|----------------------|
| | Name of Committee | Whether Regular chairperson appointed | Name of Committee members | Category (Chairperson/Executive/Non-Executive/Independent/ Nominee) \$ | Date of Appointment | Date of Cessation |
| | 1. Audit Committee | Yes | Mr. Chandrakant Khetan Mr. Mannalal B. Agrawal Mr. K H Viswanathan Mr. Prabhakar Dalal | Independent Director, Chairman of Committee Non-Executive Chairperson of Company, Member of Committee Independent Director, Member of Committee Independent Director, Member of Committee | 23-10-2008 15-07-2000 29-07-2013 05-08-2014 | |
| | 2. Nomination & Remuneration Committee | Yes | Mr. Prabhakar Dalal Mr. Chandrakant Khetan Mr. K H Viswanathan Dr. Anjana Grewal | Independent Director, Chairman of Committee Independent Director, Member of Committee Independent Director, Member of Committee Independent Director, Member of Committee | 05-08-2014 27-01-2014 29-07-2013 30-04-2019 | |
| | 3. Risk Management Committee | Yes | Mr. Yogesh M. Agrawal Mr. Rajesh M. Agrawal Mr. K H Viswanathan Mr. Arvind K. Agrawal | Managing Director, Chairman of Committee Joint Managing Director, Member of Committee Independent Director, Member of Committee Chief Financial Officer, Member of Committee | 09-08-2017 09-08-2017 30-04-2021 09-08-2017 | |
| and the second | 4. Stakeholders Relationship Committee | Yes | Mr. Mannalal B. Agrawal Mr. Rajesh M. Agrawal Dr. Anjana Grewal | | 30-04-2019 29-07-2013 05-08-2014 | |



| Date(s) of Meeting (if | Date(s) of Meeting (if | Whether requirement | Number of | Number of Independent | Maximum gap between any two |
|---------------------------|----------------------------|---------------------|-----------|-----------------------|---------------------------------|
| any) in the previous | any) in the relevant | of Quorum met* | Directors | directors' present * | consecutive (in number of days) |
| quarter | quarter | | present * | | |
| 10 th May 2022 | 28 th July 2022 | Yes | 8 | 4 | 78 |

| IV. Meeting of Committees | | | | | | |
|--|---------------------|-----------|----------------------|---------------------------|--------------------------------|--|
| Date(s) of meeting of the | Whether requirement | Number of | | | Maximum gap between any two | |
| committee in the relevant | of Quorum met* | Directors | Independent | the committee in the | consecutive meetings in number | |
| quarter | | present * | directors' present * | previous quarter | of days* | |
| 28 th July 2022 | Yes | 4 | 3 | 10 th May 2022 | 78 | |
| * This information has to be mandatorily be given for audit committee, for rest of the committee giving this information is optional | | | | | | |
| **to be filled in only for the current quarter meetings | | | | | | |

| V. Related Party Transactions | |
|---|---|
| Subject | Compliance status (Yes/No/NA) refer note below |
| Whether prior approval of audit committee obtained | Yes |
| Whether shareholder approval obtained for material RPT | Material RPTs are only with Wholly Owned subsidiary of the Company and shareholder's approval |
| | is not required for such RPTs as per Regulation 23(5) of the Listing Regulations. |
| Whether details of RPT entered into pursuant to omnibus | Yes |
| approval have been reviewed by Audit Committee | |
| NI-L | |

Note:

1. In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.

2. If status is "No" details of non-compliance may be given here.



VI. Affirmations

1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

- 2. The composition of the following committees is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
 - a. Audit Committee
 - b. Nomination & Remuneration committee
 - c. Stakeholders relationship committee
 - d. Risk management committee (applicable to the top 1000 listed entities): Applicable

HARM

- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 5. This report will be placed before Board of Directors at the ensuing Board meeting.

Name & Designation: Gaurang Shah

Company Secretary / Compliance Officer

Format to be submitted by listed entity at the end of 6 months from the close of financial year

| Regulation Number | Compliance status (Yes/No/NA) refer note below |
|--------------------------------------|---|
| | Yes |
| 18(1)(d) | Yes |
| 19(3) | Yes |
| 20(3) | Yes |
| 34(3) read with para C of Schedule V | Yes |
| | 46(2) 18(1)(d) 19(3) 20(3) |

Note

1. In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.

2. If status is "No" details of non-compliance may be given here.

3. If the Listed Entity would like to provide any other information the same may be indicated here.

Name & Designation: Gaurang C Shah

Company Secretary / Compliance Officer / Managing Director / CEO /CFO: Company Secretary & Compliance Officer

HARM

op ajanta pharma limited

Ajanta House, Charkop, Kandivli (West), T +91 22 6606 1000

F +91 22 6606 1200

Format to be submitted twice a year, on a half yearly basis by the listed entity at the end of every tapharma.com 6 months of the financial year

Half year ending 30th September 2022

| I. Disclosure of Loans / guaran | tees / comfort letters / securit | ies etc. refer note below |
|--|---|---|
| (A) Any loan or any other form | of debt advanced by the listed | l entity directly or indirectly to: |
| Entity | Aggregate amount advanced during six months | Balance outstanding at the end of six months |
| Promoter or any other entity controlled by them | Nil | Nil |
| Promoter Group or any other entity controlled by them | Nil | Nil |
| Directors (including relatives) or any other entity controlled by them | Nil | Nil |
| KMPs or any other entity controlled by them | Nil | Nil |

(B) Any guarantee/comfort letter (by whatever name called) provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt

| Entity | Type (guarantee, comfort letter etc.) | Aggregate amount of issuance during six months | Balance outstanding at the end of six months (taking into account any invocation) |
|---|--|--|---|
| Promoter or any other entity controlled by them | Nil | Nil | Nil |
| Promoter Group or any other entity controlled by them | Nil | Nil | Nil |
| Directors (including relatives) or any other entity controlled by them | Nil | Nil | Nil |
| KMPs or any other entity controlled by them | Nil | Nil | Nil |

| (C) Any security provi loan(s) or any other for | | directly or indirectly, in | connection with any |
|---|---|--|--|
| Entity | Type of security (cash, shares etc.) | Aggregate value of security provided during six months | Balance outstanding at the end of six months |
| Promoter or any other entity controlled by them | Nil | Nil | Nil |



op) ajanta pharma limited

Ajanta House, Charkop, Kandivli (West),

T +91 22 6606 1000 F +91 22 6606 1200 E info@ajantapharma.com pharma.com

| | | Mumbai 400 067 | E info@ajantap |
|---|-----|----------------------|-----------------------------|
| Promoter Group or any other entity controlled by them | Nil | India ^{Nil} | W ^{il} www.ajantap |
| Directors (including relatives) or any other entity controlled by them | Nil | Nil | Nil |
| KMPs or any other entity controlled by them | Nil | Nil | Nil |

II. **Affirmations:**

All loans (or other form of debt), guarantees, comfort letters (by whatever name called) or securities in connection with any loan(s) (or other form of debt) given directly or indirectly by the listed entity to promoter(s), promoter group, director(s) (including their relatives), key managerial personnel (including their relatives) or any entity controlled by them are in the economic interest of the company.

ARM MUMBAI

Arvind Agrawal

CFO 12 Note

1. These disclosures shall exclude any loan (or other form of debt), guarantee / comfort letter (by whatever name called) or security provided in connection with any loan or any other form of debt;

- a) by a government company to/ for the Government or government company
- b) by the listed entity to/for its subsidiary [and joint-venture company] whose accounts are consolidated with the listed entity
- c) by a banking company or an insurance company; and
- d) by the listed entity to its employees or directors as a part of the service conditions

2. If the Listed Entity would like to provide any other information, the same may be indicated as Para D in the above table.

Date: 03/10/2022